文献速递肝病

美国MASLD药物治疗的健康与经济影响模型

Modeling the health and economic impact of pharmacologic therapies for MASLD in the United States.
PubMed 文献 · J Hepatol · 2025-01-18

该研究采用美国MASLD疾病负担马尔可夫模型,模拟五种情景下药物治疗对疾病进展和经济负担的影响。仅逆转脂肪变的治疗对累积慢性肝病病例和节省的医疗费用影响极小(<1%至2%);

要点

  • 仅逆转脂肪变的治疗对累积慢性肝病病例和节省费用影响极小(<1%至2%)。
  • 假设阻止纤维化进展的治疗可减少失代偿期肝硬化11%至39%、肝细胞癌10%至34%、肝相关死亡8%至31%。

核心结论

  • 提高对中重度纤维化MASLD人群的诊断和治疗可预防晚期肝病和死亡,并减少相关直接医疗费用。
  • 提高认知、筛查和诊断,同时引入阻止纤维化进展的药物治疗,是实现MASLD人群健康和经济获益所必需的。

研究设计与样本

  • 美国MASLD疾病负担模型为马尔可夫模型,用于预测疾病进展及诊断和治疗的影响。
  • 模型纳入所有患者的诊断费用和MASLD相关肝病患者的直接费用。
  • 模拟五种情景:无治疗情景,以及四种纳入逐渐提高认知、筛查和诊断并联合抗脂肪变治疗和未来假设阻止纤维化进展治疗的干预情景。

主要发现

  • 仅逆转脂肪变的治疗对累积慢性肝病病例和节省的医疗费用影响极小(<1%至2%)。
  • 假设阻止纤维化进展的治疗情景使失代偿期肝硬化病例减少11%至39%。
  • 假设阻止纤维化进展的治疗情景使肝细胞癌病例减少10%至34%。
  • 假设阻止纤维化进展的治疗情景使肝相关死亡减少8%至31%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common condition leading to chronic liver disease, which generates substantial healthcare costs. Our aim was to model the impact of a hypothetical pharmacologic therapy that halts MASLD fibrosis progression on disease and economic burden. METHODS: The US MASLD disease burden model is a Markov model which forecasts disease progression and the impact of diagnosis and treatment. Diagnostic costs for all patients and direct costs for patients with MASLD-related liver disease were also incorporated. MASLD disease burden and economic impacts were modeled for five scenarios: a no treatment case and four interventions incorporating the impact of gradually increasing awareness, screening, and diagnosis, and treatment with anti-steatotic therapy and a future, hypothetical therapy that halts fibrosis progression. RESULTS: Treatment with therapy which only reverses steatosis had minimal (<1 to 2%) effect on cumulative chronic liver disease cases and healthcare costs averted. The scenarios in which a hypothetical therapy halts fibrosis progression resulted in reductions in cases of decompensated cirrhosis (11-39%), hepatocellular carcinoma (10-34%), and liver-related deaths (8-31%), a 9-31% reduction in cumulative DALYs, and $40.5 to $99.1B incremental healthcare costs averted. CONCLUSIONS: Increasing diagnosis and treatment for the MASLD population with moderate-to-advanced fibrosis will prevent advanced liver disease and death and will result in reducing the associated direct healthcare costs. Increasing awareness, screening and diagnosis along with introducing pharmacologic therapies that halt fibrosis progression are necessary to realize health and economic benefits for the MASLD population. IMPACT AND IMPLICATIONS: Metabolic dysfunction-associated steatotic liver disease (MASLD), the most rapidly increasing and prevalent cause of chronic liver disease, is associated with substantial healthcare costs. As disease burden and costs mount, pharmacologic therapy which halts MASLD fibrosis progression is coming to fruition. Modeling the impact on disease progression of a hypothetical pharmacologic therapy which halts MASLD fibrosis progression through multiple scenarios provides insights into the key drivers of the disease and costs associated with it. This should help to facilitate best policies and practices to mitigate the burden of MASLD.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Wallace C, Gamkrelidze I, Estes C, et al. Modeling the health and economic impact of pharmacologic therapies for MASLD in the United States. J Hepatol. 2025. PMID: 39832655. doi:10.1016/j.jhep.2025.01.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。